For example, the BRAF point mutation (T1799A) occurs in 45% of papillary thyroid carcinomas and is associated with poor clinical outcome, but its high frequency limits its usefulness to address clonality [38]. This evidence concerns the gene BRAF and thyroid gland papillary carcinoma.